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BACKGROUND AND PURPOSE
Combretastatin A-4 3-O-phosphate (CA4P) is in clinical trial as a tumour vascular disrupting agent (VDA) but the cause of
blood flow disruption is unclear. We tested the hypothesis that activation of Rho/Rho kinase (ROCK) is fundamental to the
effects of this drug in vivo.
EXPERIMENTAL APPROACH
Mouse models of human colorectal carcinoma (SW1222 and LS174T) were used. Effects of the ROCK inhibitor, Y27632, alone
or in combination with CA4P, on ROCK activity, vascular function, necrosis and immune cell infiltration in solid tumours were
determined. Mean arterial BP (MABP) was measured to monitor systemic interactions and the vasodilator, hydralazine, was
used to control for the hypotensive effects of Y27632.
KEY RESULTS
Y27632 caused a rapid drop in blood flow in SW1222 tumours, with recovery by around 3 h, which was paralleled by MABP
changes. Y27632 pretreatment reduced CA4P-induced ROCK activation and partially blocked CA4P-induced tumour vascular
effects, in both tumour types. Y27632 also partially inhibited CA4P-induced tumour necrosis and was associated with reduced
immune cell infiltration in SW1222 tumours. Hydralazine caused a similar hypotensive effect as Y27632 but had no protective
effect against CA4P treatment.
CONCLUSIONS AND IMPLICATIONS
These results demonstrate that ROCK activity is critical for full manifestation of the vascular activity of CA4P in vivo, providing
the evidence for pharmacological intervention to enhance the anti-tumour efficacy of CA4P and related VDAs.
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Introduction
Colchicine-related microtubule depolymerizing agents are
the largest family of low MW drugs to have tumour vascular
disrupting activity at relatively non-toxic doses (Tozer et al.,
2005; Kanthou and Tozer, 2007; Siemann, 2011). Combret-
astatin A-4 3-O-phosphate (CA4P or fosbretabulin/Zybrestat;
Pettit et al., 1989; 1995) was the first of this class of vascular
disrupting agents (VDAs) to enter clinical trials (Dowlati
et al., 2002; Rustin et al., 2003). Preclinical studies showed
that anti-tumour activity of CA4P was dependent on dose,
scheduling, tumour type and vascular characteristics (Boehle
et al., 2001; Hill et al., 2002; Tozer et al., 2008a), with particu-
lar efficacy in combination with conventional chemotherapy
or radiotherapy (Murata et al., 2001b; Siemann et al., 2002).
CA4P has progressed to phase II trials in patients with
relapsed ovarian cancer and to phase III trials in patients
with anaplastic thyroid cancer, primarily in combination
with conventional chemotherapy (http://www.oxigene.com/
product-development/zybrestat).
Shortly after administration in vivo, CA4P is cleaved to the
active form, CA4, (Stratford and Dennis, 1999), which has
been shown to bind β-tubulin resulting in microtubule desta-
bilization and net depolymerization (McGown and Fox,
1989). The effects of well-tolerated doses of CA4P in vivo are
evident almost immediately by a rapid and selective decrease
and loss of tumour blood flow, which becomes maximal
between 1 and 4 h after administration and can remain
lowered in both animal and human tumours for up to 24 h
before vasculature re-establishes itself (Dark et al., 1997;
Murata et al., 2001a; Prise et al., 2002; Galbraith et al., 2003).
Central tumour necrosis is apparent within 24 h of treatment
accompanied by leucocyte infiltration into the tumour mass.
Tumour-infiltrating Tie2-positive macrophages act to reduce
CA4P-induced tumour vascular injury or to aid recovery of
the vasculature following drug exposure (Welford et al.,
2011). A similar effect was ascribed to endothelial progenitor
cells, mobilized from the bone marrow by a second-
generation combretastatin, combretastatin A-1 diphosphate
(Oxi4503; Shaked et al., 2006). Myeloperoxidase (MPO) accu-
mulation in CA4P-treated tumours (Parkins et al., 2000) also
suggested a role for neutrophils in determining the ultimate
fate of tumour cells following VDA treatment.
In endothelial cells in vitro, CA4-induced depolymeriza-
tion of interphase microtubules is accompanied by genera-
tion of actinomyosin contractility and reorganization of the
actin cytoskeleton through activation of Rho-GTPase (Rho)/
Rho kinase (ROCK) and MAPK signalling (Kanthou and Tozer,
2002). Indeed, actin stress fibres and focal adhesions form
very rapidly after treatment with CA4P while some endothe-
lial cells assume a rounded ‘blebbing’ morphology, probably
through increased contractility as well as elevated p38 SAPK
activity (Kanthou and Tozer, 2002). Disruption of cell–cell
junctions leading to gap formation and increased monolayer
permeability to macromolecules is also a feature of the early
response of endothelial cells to CA4P driven by Rho/ROCK
(Kanthou and Tozer, 2002; Vincent et al., 2005). Additionally,
the rounding of endothelial cells and the loss of cell-to-cell
adhesions was shown to be associated with CA4P inhibition
of vascular endothelial cadherin and β-catenin complexes
and the inhibition of the PI3K/Akt pro-survival signalling
pathway (Vincent et al., 2005). Blood flow disruption in solid
tumours is accompanied by an increase in vascular perme-
ability to macromolecules (Reyes-Aldasoro et al., 2008), par-
alleling effects observed for endothelial cells in vitro and
suggesting that knowledge gained from in vitro studies is
useful for deciphering mechanisms associated with drug
activity in vivo.
Activation of Rho/ROCK signalling following CA4P
administration in vitro was established using inhibitors such
as recombinant C3 exoenzyme of clostridium botulinum that
inhibits Rho and the ROCK inhibitor Y27632 (Kanthou and
Tozer, 2002). These studies showed that the increase in
endothelial cell monolayer permeability, as well as the mor-
phological changes induced by CA4P in vitro, was Rho/ROCK
dependent. Establishing the links between Rho/ROCK signal-
ling activation and cytoskeletal effects of CA4P in endothelial
cells has advanced an understanding of the mechanism of
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action of CA4P. However, whether there is any involvement
of Rho signalling in the mechanism of action of CA4P in vivo
is unknown. The ROCK inhibitor, Y27632, was originally
developed as an anti-hypertensive agent (Uehata et al., 1997).
This compound has been extensively used in vivo to demon-
strate key roles of ROCK in many other processes including
inflammation and ischaemia-reperfusion (I-R) injury (Bao
et al., 2004; Hamid et al., 2007). Using this agent, the aim of
the current study was to determine the role of the Rho/ROCK
signalling pathway in CA4P-induced vascular shutdown,
necrosis induction and leucocyte infiltration in two human
colorectal xenografted tumour models in mice. We controlled
for the potent hypotensive effect of Y27632 by comparing its
effects with those of the direct vasodilator, hydralazine
(Sawada et al., 2000; Wang et al., 2008). We found a protective
effect of Y27632 but not hydralazine against CA4P, demon-
strating an important role for ROCK activity in the mecha-
nism of action of this tumour VDA in vivo.
Materials and methods
Cell systems
The human colorectal carcinoma cell lines SW1222 (kindly
provided by Dr R B Pedley, University College London) and
LS174T (European Collection of Cell Cultures) were main-
tained in DMEM supplemented with 10% foetal calf serum,
100 U mL−1 penicillin, 100 µg mL−1 streptomycin and 2 mM
L-glutamine (Lonza, Cambridge UK).
The purity of the SW1222 cell line was verified by rou-
tinely checking for its characteristic glandular morphology,
when established in vivo (Richman and Bodmer, 1988) and by
performing PCR-based microsatellite genotyping analysis
[Health Protection Agency (HPA), UK]. Fingerprint baseline
information was not available for the SW1222 line. However,
the generated profile of the SW1222 cells was unique when
compared with profiles of all human cell lines in the HPA
database. LS174T cells were used at early passages only.
Animals and tumours
All animal care and experimental procedures were carried out
in accordance with the UK Animals (Scientific Procedure) Act
1986, with local ethics committee approval and following
published guidelines for the use of animals in cancer research
(Workman et al., 2010). All studies involving animals are
reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals (Kilkenny et al.,
2010; McGrath et al., 2010). A total of 336 animals were used
in the experiments described here.
Mice were provided with regular mouse chow and water
ad libitum and kept on a 12 h light/dark cycle. Tumour cells (5
× 106 in non-supplemented DMEM) were implanted subcuta-
neously onto the rear dorsum of mixed sex 8–12-week-old
severe compromised immune-deficient (SCID) mice. Tumours
were selected for treatment 12–20 days post-implantation,
when the geometric mean diameter reached 6–7 mm.
Drug treatment
All drugs were administered i.p. at 10 mL kg−1 in physiologi-
cal saline. Mice were killed at 1, 3, 6 or 24 h after single-dose
CA4P treatment (OxiGene Inc., San Francisco, CA, USA), at
100 mg kg−1; a previously determined effective dose for
SW1222 tumours (Lunt et al., 2011). Y27632 (Tocris Biosci-
ence, Bristol, UK) was administered at the maximum toler-
ated dose in our mice of 50 mg kg−1 (unpublished data), either
alone or 5 min before or 3 h after CA4P treatment. Twice
daily doses of 50 mg kg−1 Y27632 have been used previously
in mice (Mavria et al., 2006). Hydralazine (Sigma-Aldrich Co
Ltd, Gillingham, UK) was administered at 2 mg kg−1, either
alone or 5 min before CA4P treatment, to induce a similar
hypotensive effect to that of Y27632 (Sawada et al., 2000;
Wang et al., 2008).
Arterial BP
The effect of drug treatment on mean arterial BP (MABP) in
unanaesthetized, non-tumour-bearing mice was measured via
an occlusion and plethysmograph tail cuff system (Kent Sci-
entific Corporation, Torrington, CT, USA). Mice were accli-
matized to the equipment for a minimum of 1 h·day−1 for 7
days prior to drug treatments. MABP was calculated as [(dias-
tolic pressure ×2) + systolic pressure]/3. MABP in mmHg was
recorded in triplicate before and at various times up to 24 h
after i.p injection of Y27632 ± CA4P, with relevant saline
controls. Values were averaged for each time point.
Laser Doppler flowmetry
In order to monitor acute effects of drug treatments in indi-
vidual animals, relative changes in volumetric tumour micro-
vascular red cell flux were measured using the Oxyflo™ laser
Doppler perfusion system (Oxford Optronix Ltd, Oxford,
UK). Mice were anaesthetized with isoflurane (maintenance
dose of 1.5–2.0% in oxygen) and maintained on a thermo-
statically controlled heating pad throughout. Up to four
probes of <1 mm diameter were inserted into the tumour at
various depths. Once readings were stable (approximately
20 min), mice were injected i.p with Y27632 (50 mg kg−1) or
vehicle control (saline) and readings taken for a further 5
minute period. Animals were then injected i.p with CA4P
(100 mg kg−1) or vehicle control (saline) and readings taken
for a further 120 min, followed by killing of the animals by an
i.v. overdose of sodium pentobarbitone. Post mortem baseline
readings for each probe were subtracted from probe readings
obtained throughout the experiment. Data were expressed as
a percentage of the pretreatment value.
Perfusion index
Mice were treated as above and the tumour perfusion index
calculated at 1, 3, 6 or 24 h after CA4P, as published previ-
ously (Lunt et al., 2011). Briefly, 0.2 mg FITC-conjugated
Lycopersicon esculentum tomato lectin (Vector Laboratories,
Peterborough, UK) per mouse was injected 5 min before
killing to detect perfused blood vessels at the time of lectin
injection. Excised tumours were rapidly frozen and cryo-
sections immuno-stained for platelet endothelial cell
adhesion molecule (CD31), using Alexa-Fluor 555 for visuali-
zation, to detect both perfused and unperfused blood vessels.
Detailed methods for staining and image capture are
described in Supporting Information Appendix S1.
Individual captured images were analysed using in-house-
developed Matlab-based software. Fluorescence channels
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were manually thresh-holded for each individual tumour.
The perfusion index for each image was calculated as the
number of pixels positive for FITC as a percentage of the
number of pixels positive for Alexa-Fluor 555.
Histology and immunohistochemistry
Tumours from animals culled at 24 h after treatment were
fixed, sectioned and stained with haematoxylin and eosin for
necrosis scoring, immuno-stained for MPO for identification
of neutrophils or immuno-stained for the phosphorylated
form of the ROCK substrate protein complex ezrin-radixin-
moesin (p-ERM) as a marker of ROCK activation (Matsui
et al., 1998).
Necrosis was scored according to a random points scoring
system. Whole tumour sections were scanned using an eye-
piece graticule marked with 25 random points (Chalkley grid)
and a ×20 objective. Approximately 150 regions were scanned
per tumour. Necrosis was identified by reduced cellular
density, pale cytoplasm and pyknotic nuclei or completely
disrupted cells. The number of points falling on necrotic
tissue as a % of total points counted was used to calculate
necrosis as a % of the total sectional area.
A rabbit anti-mouse polyclonal antibody (Dako, Ely, UK;
1:150 dilution) was used for MPO staining, as described in
detail in Supporting Information Appendix S1. A Chalkley
grid was used, as described above, for scoring MPO in necrotic
areas, where staining was widespread. A squared eyepiece grid
and a ×20 objective were used for scoring MPO in viable tissue
areas, where staining was sparse. The grid was systematically
moved across viable areas and all positive-stained cells were
counted within the grid. Necrotic and viable scores were
combined to calculate the total MPO staining as a % of the
total tumour section area.
A rabbit monoclonal antibody (Cell Signaling, Hertford-
shire, UK) was used to detect p-ERM, as described in Support-
ing Information Appendix S1. Sections were scanned and
p-ERM staining was calculated as % of total viable section
area using the Scanscope CS® system (Aperio, Vista, CA,
USA).
Data analysis
Results are shown as means ± SEM. Statistical analysis was
carried out using GraphPad Prism software Version 5.0d for
Macintosh (GraphPad Software Inc., San Diego, USA). MABP
and laser Doppler data were analysed using a two-way ANOVA
with repeated measures followed by a Bonferroni post hoc test.
Perfusion index data for SW1222 tumours determined at dif-
ferent time points after CA4P treatment were analysed by a
two-way ANOVA followed by a Bonferroni post hoc test. Stu-
dent’s t-test (for comparison of two groups) or a one-way
ANOVA followed by a Bonferroni or Newman–Keuls post hoc
test (for comparison of more than two groups) were used for
all other data sets. In all cases, differences between treatment
groups were described as significant if the probability corre-
sponding to the relevant statistic was less than 0.05.
Results
Efficacy of Y27632 in solid tumours in vivo
In order to determine the efficacy of the ROCK inhibitor
Y27632 in vivo, we used p-ERM as a marker for ROCK activa-
tion (Hamid et al., 2007). Figure 1 shows that p-ERM in
control saline-treated SW1222 tumours was primarily
detected in the stroma, most likely associated with endothe-
lial cells, where moesin is known to be the most prevalent of
this specialized family of proteins (Fehon et al., 2010). Treat-
ment with CA4P caused a marked increase in the intensity
and pervasiveness of p-ERM staining both in the stroma and
on tumour cells (Figure 1). Staining of tumour cells was con-
fined to the cell periphery, consistent with the known loca-
tion of ERM proteins on cell membranes, where they interact
with trans-membrane proteins and the cytoskeleton to
control a diverse range of cellular functions (Fehon et al.,
2010). Y27632 alone had no effect on p-ERM expression
(Figure 1) but pretreatment with Y27632 blocked the increase
in p-ERM expression observed for CA4P treatment adminis-
tered alone (Figure 1).
Systemic effects
Y27632 is a hypotensive agent, acting on vascular smooth
muscle cells and the sympathetic nervous system (Ito et al.,
2003; Moosmang et al., 2003). In order to control for these
effects, we also used hydralazine, a direct acting vascular
smooth muscle relaxant that has been used previously for
similar purposes (Sawada et al., 2000) (Wang et al., 2008).
Figure 2A shows that Y27632 and hydralazine, at the chosen
doses, had similar and rapid hypotensive effects. CA4P alone
caused a small increase in MABP (Figure 2A), which is con-
sistent with previous results for both rat and man (Galbraith
et al., 2003). It should be noted that 100 mg kg−1 CA4P has
been used commonly in mice but, on a body surface area
basis, this is approximately four times the maximum toler-
ated dose in man (Rustin et al., 2003). Doses of around
10 mg kg−1 have activity in rodent models of cancer (Prise
et al., 2002) but our aim here was to ensure we achieved a
profound CA4P-induced tumour vascular response for mean-
ingful testing of the ROCK inhibitor, Y27632. The combina-
tion of either Y27632 or hydralazine with CA4P dropped
MABP to similar levels as Y27632 or hydralazine alone but
return to control levels was somewhat delayed for both com-
bination groups (Figure 2A). By 24 h after treatment, MABP
was the same for all groups, with no obvious signs of toxicity.
Effects of ROCK inhibition on tumour
vascular disrupting properties of CA4P
Early tumour vascular effects were first studied in SW1222
tumours using laser Doppler flowmetry. Figure 2B) shows a
similar and substantial drop in red cell flux to approximately
40% of pretreatment levels for both Y27632 and CA4P
administered as single agents. The time course of the decrease
for Y27632 alone was significantly different from the control
group by 5 min after administration and very similar to that
for MABP (Figure 2A), implicating a decrease in perfusion
pressure as the stimulus for blood flow reduction. The reduc-
tion in tumour red cell flux following CA4P treatment was
somewhat slower than for Y27632 (significantly different
from the control group by 20 min after administration) but
reached similar low levels by 30–40 min, with a further slow
decline during the remaining time course of the experiment.
In this case, as reported previously (Tozer et al., 1999; Ke et al.,
2009), the blood flow effects could not be explained by a
BJPRho kinase and tumour vascular targeting
British Journal of Pharmacology (2014) 171 4902–4913 4905
decrease in perfusion pressure, as CA4P caused a moderate
hypertensive effect, when administered as a single agent
(Figure 2A). Combination of Y27632 and CA4P resulted in a
sustained decrease in red cell flux that was almost identical to
that for Y27632 alone, with no indication of any additive
effect. There was no statistical difference in red cell flux
between the three drug-treated groups by the end of the
experiment (2 h after drug administration).
Figure 3A shows representative images for FITC-lectin and
CD31 staining in frozen sections of SW1222 tumours, follow-
ing in vivo administration of CA4P or vehicle ± Y27632.
Figure 3B (left panel) shows the calculated perfusion index
(FITC-lectin staining as a % of CD31 staining) from 1 to 24 h
following in vivo administration of CA4P or vehicle ± Y27632.
Results show that the tumour perfusion index following
Y27632 treatment alone had returned to control levels by 3 h,
Figure 1
(A) Representative staining images for p-ERM in control saline-treated SW1222 tumours; 24 h after Y27632 (50 mg kg−1) alone; 24 h after CA4P
(100 mg kg−1) treatment alone; 24 h after combination of Y27632 administered 5 min prior to CA4P. CA4P treatment resulted in more intense
and pervasive staining, especially in cell membranes of tumour cells, as shown in the magnified inset. Y27632 treatment alone and the
combination treatment resulted in moderate levels of staining comparable to control. (B) Quantification data for all the four groups. Columns
represent mean ± SEM for n = 8–11 mice per group. *P < 0.05, significant difference between groups (one-way ANOVA with Bonferroni post test).
BJP L J Williams et al.
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consistent with a recovery in perfusion pressure, as implied
by the BP data shown in Figure 2A. The perfusion index
following CA4P treatment alone declined steadily for at least
24 h, at which time lectin staining was only approximately
5% of CD31 staining. Pretreatment of CA4P-treated mice
with Y27632 partially prevented the protracted decline in
perfusion index found for CA4P alone, resulting in a perfu-
sion index of 20% compared with approximately 10% for
CA4P alone at 6 h and 20% compared with 5% for CA4P
alone at 24 h. These differences were statistically significant.
In contrast, administration of hydralazine prior to CA4P had
no protective effect at 24 h (right-hand panel in Figure 3B).
Administration of Y27632 3 h after CA4P had no protective
effect on the perfusion index at 6 or 24 h post-CA4P treat-
ment (Supporting Information Figure S1). Pretreatment with
Y27632 had a similar protective effect in the LS174T tumour
as in the SW1222 tumour, assayed at 24 h after CA4P treat-
ment (Figure 3C). The perfusion index was partially and sig-
nificantly maintained to approximately 20%, compared with
approximately 5% for CA4P alone. However, unlike in the
SW1222 tumour, no protective effect was apparent at 6 h
after CA4P treatment.
Effects of ROCK inhibition on induction of
tumour necrosis by CA4P
Figure 4 shows the effect of Y27632, CA4P and the combina-
tion treatment on necrosis induction at 24 h after CA4P treat-
ment in the two tumour types. Figure 4A and B shows that
necrosis in SW1222 tumours was less than 20% in control
and Y27632-treated tumours, with no significant difference
between necrosis levels in the two groups, whereas CA4P
treatment significantly increased necrosis to more than 60%.
Pretreatment with Y27632 partially blocked this effect, such
that necrosis levels were below 40% and significantly differ-
ent from levels in both control and CA4P-treated groups.
However, as for the vascular effects shown in Figure 3,
hydralazine had no effect on CA4P-induced tumour necrosis
(Figure 4B). Administration of Y27632 3 h after CA4P also
had no effect (Figure 4B). Figure 4C shows the equivalent
results for the LS174T tumours. Control necrosis levels were
very high in these tumours equating to approximately 60% of
the sectional areas, with similar levels found for Y27632-
treated tumours, and with no significant increase following
CA4P treatment. No significant differences were found for
necrosis levels between any of the treatment groups for this
tumour type, despite the significant vascular effects shown in
Figure 3.
Effects of ROCK inhibition on MPO
expression following CA4P treatment
Very little MPO expression was detected in control untreated
SW1222 tumours or the same tumours treated with Y27632
alone (≤0.1% of the sectional area; Figure 5A and B). There
was significantly increased MPO expression, to approxi-
mately 1.5%, in SW1222 tumours 24 h after CA4P treatment
but there was large variability in MPO expression between
individual CA4P-treated tumours such that the apparent 50%
reduction by prior treatment with Y27632 (Figure 5A and B)
was only borderline significant (significant according to
Newman–Keuls but not Bonferroni post hoc test). MPO
Figure 2
(A) MABP measured by tail cuff plethysmography in conscious
restrained severe compromised immune-deficient mice. Open
circles, control saline treated; closed circles, CA4P (100 mg kg−1 i.p.);
open squares in upper panel, Y27632 (50 mg kg−1 i.p.); closed
squares in upper panel, Y27632 (50 mg kg−1 i.p.) administered 5 min
prior to CA4P (100 mg kg−1 i.p.); open squares in lower panel,
hydralazine (2 mg kg−1 i.p.); closed squares in lower panel, Y27632
(2 mg kg−1 i.p.) administered 5 min prior to CA4P (100 mg kg−1 i.p.).
†P < 0.05, significant difference between individual data points in the
CA4P group and the equivalent data points for the saline control
group; two-way ANOVA with repeated measures. *P < 0.05, range over
which there is a significant difference between the Y27632 and saline
control group and between the Y27632 + CA4P group and the saline
group; two-way ANOVA with repeated measures. ΦP < 0.05,range over
which there is a significant difference between the Y27632 + CA4P
group and the Y27632 alone group (upper panel) or the hydralazine
+ CA4P group and the hydralazine alone group (lower panel); two-
way ANOVA with repeated measures. Each symbol represents mean ±
SEM for 5–13 mice. (B) Tumour perfusion measured by laser Doppler
flowmetry following the same treatments as in the upper panel of A.
*P < 0.05, significant difference between the control saline group and
all other groups at the end of the observation period; two-way ANOVA
with repeated measures. No statistical difference was found between
the CA4P alone, Y27632 alone and combination treatment groups at
the end of the observation period (two-way ANOVA with repeated
measures). Each symbol represents means ± SEM for six mice.
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Figure 3
(A) Representative images of FITC-lectin and CD31 immuno-stained frozen sections from SW1222 tumours: untreated control, Y27632
(50 mg kg−1) treatment alone, CA4P (100 mg kg−1) treatment alone and the combination treatment (Y27632 5 min prior to CA4P). Tumours were
excised at 3 or 24 h after CA4P or the relevant vehicle treatment and demonstrate lack of any effect of Y27632 at the early time point and a
protective effect by 24 h. Scale bars represent 250 µm. (B) Perfusion index calculated as the number of pixels stained +ve for FITC-lectin as a %
of the number of pixels stained +ve for CD31 for whole data sets in SW1222 tumours. A full time course is shown for the effect of Y27632 on
CA4P-induced tumour vascular effects (left-hand panel; n = 5–6 for 1 and 3 hour time points; n > 9 for 6 and 24 h time points) and for 24 h after
CA4P for the effect of hydralazine on CA4P-induced tumour vascular effects (right-hand panel; n = 9 for both groups). (C) Perfusion index
calculated as above for the effect of Y27632 on CA4P-induced vascular effects in LS147T tumours at 6 and 24 h after CA4P. Points and bars
represent means ± SEM for n = 6–7. The horizontal lines represent the mean ± SEM for control untreated tumours. *P < 0.05, in B, significant
difference between groups for the full time course; †P < 0.05, significant difference at time = 6 h; two-way ANOVA. *P < 0.05, in C, significant
difference between groups; one-way ANOVA with Bonferroni post test. NS represents a non-significant difference.
BJP L J Williams et al.
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expression was primarily associated with necrotic tumour
regions in both untreated and treated tumours, although
there were also some isolated positively stained cells in viable
tumour regions (white arrows in Figure 5A).
Discussion
Pretreatment administration of the ROCK inhibitor, Y27632,
partially protected two types of colorectal carcinoma xeno-
grafts from the tumour vascular disrupting effects of the VDA,
CA4P. In the SW1222 tumour, where CA4P treatment alone
induced significant necrosis, this vascular protection was
translated into a reduction in CA4P-induced necrosis. Admin-
istration of hydralazine, which replicated the hypotensive
effect of Y27632, had no protective effect on CA4P-induced
tumour vascular disruption or necrosis in SW1222 tumours,
demonstrating that hypotension could not explain the pro-
tection found with Y27632. These results demonstrate that
Rho-GTPase/ROCK activity is critical for full manifestation of
CA4P’s vascular activity in vivo.
Immuno-staining for p-ERM demonstrated that CA4-P
induced the activation of ROCK in tumour tissue in vivo,
confirming previous results for endothelial cells (Kanthou
and Tozer, 2002) and SW1222 tumour cells (unpublished
data) in vitro. Pretreatment with Y27632 was able to block the
activation of ROCK induced by CA4P, as detected by p-ERM
expression (Figure 1). Although not the focus of this study,
the CA4P-induced increase in p-ERM expression within solid
tumours is likely to be a significant step in the mode of action
of this and similar tumour VDAs. The ERM proteins have
diverse roles in cells, which are not fully understood. They are
membrane-associated and interact with trans-membrane pro-
teins, such as tyrosine kinase receptors, and various cell adhe-
sion molecules to form complex membrane domains, which
link to the underlying cytoskeleton for signal transduction
(Fehon et al., 2010). As well as mediating ROCK-activated
remodelling of the F-actin cytoskeleton (Fehon et al., 2010),
interaction of specific ERMs with trans-membrane proteins is
thought to be a requirement for their activity as co-receptors,
for example, CD44 as a co-receptor for c-Met (Orian-Rousseau
and Ponta, 2008). There is ample evidence from preclinical
studies that CA4P is active against primary and metastatic
disease (see Tozer et al., 2005). However, the known roles of
ROCK and activated ERMs in cell migration (Fehon et al.,
2010) suggest that, as well as having a central role in the
mechanism of action of CA4P, CA4P-induced ROCK activity
may also be involved in resistance pathways emanating from
suboptimal CA4P dosing. Up-regulation of VEGF and other
pro-angiogenic proteins have been observed following CA4P
treatment (Boehle et al., 2001; Sheng et al., 2004; Shaked
et al., 2009) and ROCK activation is a key component of
downstream VEGF signalling associated with migration and
vascular permeability (van der Meel et al., 2011). These obser-
vations are consistent with preclinical and clinical studies
showing the benefit of following up a course of CA4P treat-
ment with administration of the anti-VEGF antibody, beva-
cizumab (Siemann and Shi, 2008; Nathan et al., 2012).
The protective effect of Y27632 against CA4P-induced
vascular damage in SW1222 tumours was only manifested at
relatively late times (6 and 24 h) after CA4P treatment
(Figure 3A, B), despite administration of Y27632 just prior to
CA4P and a profound effect of CA4P on tumour red cell flux
and perfusion index within the first hour of treatment
(Figure 2B and 3). A similar effect was observed for the
LS174T tumour, at 24 h (Figure 3B). The fact that no protec-
tive effect was detectable at earlier time points is not surpris-
ing in view of the rapid decrease in tumour red cell flux and
perfusion index induced by Y27632 alone. These vascular
effects are most likely driven by the hypotensive effect of
Y27632, resulting primarily from relaxation of vascular
Figure 4
(A) Representative images of haematoxylin and eosin stained
formalin-fixed sections from SW1222 tumours: untreated control,
Y27632 (50 mg kg−1) treatment alone, CA4P (100 mg kg−1) treat-
ment alone and the combination treatment (Y27632 5 min prior to
CA4P). Tumours were excised at 24 h after CA4P or the relevant
vehicle treatment. Scale bars represent 500 µm. N = necrosis; V =
viable tumour region. (B) Quantification of necrosis in SW1222
tumours for the different treatments described above (left-hand
panel) or for CA4P ± hydralazine 5 min prior to CA4P (right-hand
panel), assayed at 24 h after CA4P or the relevant vehicle treatment.
(C) Quantification of necrosis in LS147T tumours for the different
treatments shown, assayed at 24 h after CA4P or the relevant vehicle
treatment. Bars show means ± 1 SEM. *P < 0.05, significant differ-
ence between groups; one-way ANOVA followed by Bonferroni post
test. n > 8 per group for SW1222; n > 4 per group for LS174T. NS
represents a non-significant difference.
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smooth muscle cells in resistance arterioles of normal tissues
(Ito et al., 2003; Moosmang et al., 2003), which follows the
same time course as the tumour perfusion index, recovering
to control levels between 3 and 5 h (comparing Figures 2A
and 3B). There was also no additive effect of the early
decreases in red cell flux or perfusion index observed for
Y27632 and CA4P alone, when the two drugs were combined
(Figure 2B and 3B), suggesting a protective interaction
between the two drugs. In any case, once the hypotensive
and blood flow modifying effects of Y27632 alone resolved, a
protective effect of Y27632 against the vascular disrupting
effects of CA4P was clearly apparent (6 and 24 h time points
in Figure 3B), whereas no such effect was found for hydrala-
zine, despite this drug having a similar hypotensive profile.
The tumour vascular disrupting activity of CA4P is not only
due to a vasoconstrictive effect on supplying arterioles (which
also occurs in a range of normal tissues, accounting for the
mild hypertensive effect of the drug) but also to direct
damage to tumour endothelial cells (reviewed in Tozer et al.,
2008b). The fact that hydralazine did not protect against
CA4P-induced tumour vascular disruption and necrosis
strongly suggests that the protective effect of Y27632 is due to
blocking of ROCK-mediated cytoskeletal damage to tumour
endothelial cells. Staining for p-ERM showed a CA4P-induced
expression in tumour cells, as well as in tumour vasculature,
that was blocked by Y27632 treatment. However, by utilizing
SW1222 tumour cells developed to be resistant to CA4P, we
have previously shown that the anti-tumour activity of CA4P
in vivo is mediated by its tumour vascular effects, rather than
by direct toxicity towards the tumour cells themselves (Lunt
et al., 2011).
Although significant, the protective effects of Y27632
were only partial, suggesting that CA4P-induced tumour vas-
cular disruption is not totally ROCK dependent. The fact that
Figure 5
(A) Representative images of MPO immuno-staining (brown) in control untreated SW1222 tumours, 24 h after CA4P (100 mg kg−1) alone and
24 h after the combination treatment with Y27632 (50 mg kg−1) administered 5 min prior to CA4P. Staining in tumours exposed to Y27632 alone
was very similar to that in controls (image not shown). White arrows indicate representative individual positively stained cells in a viable region
of a control tumour. V represents viable and N represents necrotic tumour tissue. (B) Quantified data for all four groups. Columns represent means
± SEM for n = 8 per group. *P < 0.05 significant difference between groups; one-way ANOVA with Bonferroni post test. The difference between the
CA4P group and the combination group was borderline significant (≠) depending on the post hoc test used (see main text for details).
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the hypotensive effect of Y27632 had worn off after 3 to 5 h
is consistent with a short plasma half-life for Y27632 in mice
(van Beuge et al., 2011). This suggests that, when given before
CA4P, the drug interacts with CA4P-induced effects that occur
within the first few hours following treatment, which results
in partial protection from CA4P-induced tumour vascular
damage that is manifested when the hypotensive effect of
Y27632 has worn off. In order to check whether ROCK inhi-
bition could protect against later effects, Y27632 was also
administered 3 h after CA4P but, under these conditions, it
had no significant vascular protective effect. This supports
the notion that Y27632 is acting at an early stage in the
vascular disruptive process and is consistent with the known
activity of Y27632 in endothelial cells in vitro, where it pre-
vents the CA4P-induced cytoskeletal remodelling, cell shape
changes and increase in monolayer permeability to macro-
molecules that occur within 30 minutes of drug exposure
(Kanthou and Tozer, 2002). However, we cannot exclude the
possibility that drug access problems at 3 h after CA4P treat-
ment could explain the lack of any significant effect when
Y27632 was administered at this later time point.
I-R injury, as tumour blood vessels dilate following
initial CA4P-induced collapse and blood flow struggles to
re-establish, is likely to contribute to the outcome of VDA
treatment. As noted above, ROCK is strongly activated during
I-R in the heart and inhibition of ROCK can attenuate the
consequent injury and inflammation (Bao et al., 2004; Hamid
et al., 2007). Thus, the partial protective effect of Y27632
administration against CA4P, in our study, could involve pro-
tection against I-R injury. ROCK was found to cause injury
by inactivating pro-survival signalling via PI3K/AKT and
endothelial NOS (eNOS), thus limiting NO bioavailability
(Rikitake et al., 2005; Hamid et al., 2007). This mechanism
may apply to tumours, as NOS inhibition has been shown to
exacerbate the vascular damaging effects of CA4P (Tozer et al.,
2009). The role of neutrophils in I-R injury is well established,
with neutrophil-associated MPO contributing to production
of damaging free radicals (Rodrigues and Granger, 2010).
Here, we showed that ROCK inhibition was associated with
a substantially decreased CA4P-induced MPO expression,
which is consistent with the known role of ROCK activation
in mediating neutrophil migration and endothelial adhesion
(Alblas et al., 2001; Saito et al., 2002). However, such an asso-
ciation provides no information on cause and effect and since
MPO is expressed in activated macrophages and other granu-
locyte lineage populations, as well as neutrophils (Tavora
et al., 2009), we cannot exclude the involvement of other cell
types here. Recent evidence has shown that the net result of
Tie2 + macrophage infiltration following CA4P treatment is
to decrease the final elicited damage (Welford et al., 2011).
Similar experiments need to be carried out, ideally in
immune-competent mice, to determine whether I/R injury
associated with neutrophil infiltration acts to increase VDA-
induced tumour vascular damage or whether the net effect is
a more rapid recovery via a stimulation of angiogenesis.
In SW1222 tumours, the protective effect of Y27632 was
translated into a protective effect on CA4P-induced necrosis.
However, this was not the case for the LS174T tumour, in
which Y27632 caused a similar protective effect against
CA4P-induced vascular damage as it did in the SW1222
tumours but had no effect on necrosis induction. This is not
surprising in view of the very high levels of necrosis already
present in untreated LS174T tumours, which CA4P treatment
did not affect. Untreated LS174T tumours are also very
hypoxic (Professor R Barbara Pedley, University College
London, pers. comm.) suggesting that CA4P may be ineffec-
tive against them, in terms of necrosis induction, because the
tumour cells are adapted to survival under hypoxic condi-
tions. A higher dose of CA4P than used here has previously
been reported to increase necrosis in LS174T tumours but to
a much lesser extent than in SW1222 tumours (Pedley et al.,
2002), which is consistent with our result.
We have found that activation of the Rho/ROCK signal-
ling pathway plays an important role in the vascular disrupt-
ing action of CA4P in vivo, which translates into necrosis
induction in CA4P-responsive tumours. It is likely that this is
also the case for closely related drugs currently in clinical
trial, such as Oxi4503 and ombrabulin. Since increased ROCK
is known to exacerbate injury in other disease states via
inactivation of pro-survival signalling via PI3K/AKT and
eNOS, the current data provides a mechanistic explanation
for the efficacy of combining NOS inhibition with CA4P. It
also provides a rationale for investigating pharmacological
intervention at other points in the pro-survival pathway for
therapeutic benefit in combination with VDAs. The current
results suggest that other classes of agents that activate Rho/
ROCK signalling have potential as VDAs, such that this sig-
nalling pathway could form the basis of a useful drug screen.
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Figure S1 Perfusion index calculated as the number of pixels
stained + ve for FITC-lectin as a % of the number of pixels
stained + ve for CD31 at 6 and 24 h after CA4P for CA4P alone
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Y27632 at either time point (two-way ANOVA with Bonferroni
post test).
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